Publications Resulting From Direct Support by the Radionuclide Resource for Cancer Applications
Click on one of the following:
Publications
 2008
  1. Alidori S, Gioia Lobbia G, Papini G, Pellei M, Porchia M, Refosco F, et al. Synthesis, in vitro and in vivo characterization of 64Cu(I) complexes derived from hydrophilic tris(hydroxymethyl)phosphane and 1,3,5-triaza-7-phosphaadamantane ligands. Journal of Biological Inorganic Chemistry. 2008;13:307-15.
  2. Anderson CJ, Wadas TJ, Wong EH, Weisman GR. Cross-bridged macrocyclic chelators for stable complexation of copper radionuclides for PET imaging. Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2008;52:185-92.
  3. Basken NE, Mathias CJ, Lipka AE, Green MA. Species dependence of [64Cu]Cu-Bis(thiosemicarbazone) radiopharmaceutical binding to serum albumins. Nuclear Mediciine and Biology. 2008;35:281-86.
  4. Bonnitcha PD, Vãvere AL, Lewis JS, Dilworth JR. In Vitro and In Vivo Evaluation of Bifunctional Bisthiosemicarbazone 64Cu-Complexes for the Positron Emission Tomography Imaging of Hypoxia. Journal of Medicinal Chemistry. 2008;51:2985-91.
  5. Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ. Assessing Tumor Hypoxia in Cervical Cancer by PET with 60Cu-Labeled Diacetyl-Bis(N4-Methylthiosemicarbazone). Journal of Nuclear Medicine. 2008;49:201-05.
  6. Edwards WB, Xu B, Akers W, Cheney PP, Liang K, Rogers BE, et al. Agonist-Antagonist Dilemma in Molecular Imaging: Evaluation of a Monomolecular Multimodal Imaging Agent for the Somatostatin Receptor. Bioconjugate Chemistry. 2008;19:192-200.
  7. Eiblmaier M, Meyer LA, Anderson CJ. The role of p53 in the trafficking of copper-64 to tumor cell nuclei. Cancer Biology and Therapy. 2008;7:63-69.
  8. Fukukawa K-i, Rossin R, Hagooly A, Pressly ED, Hunt JN, Messmore BW, et al. Synthesis and Characterization of Core-Shell Star Copolymers for In Vivo PET Imaging Applications. Biomacromolecules. 2008;9:1329-39.
  9. Kim Y-S, Yang C-T, Wang J, Wang L, Li Z-B, Chen X, et al. Effects of Targeting Moiety, Linker, Bifunctional Chelator, and Molecular Charge on Biological Properties of 64Cu-Labeled Triphenylphosphonium Cations. Journal of Medicinal Chemistry. 2008;51:2971-84.
  10. Laforest R, Liu X. Imaging With Non-Standard Nuclides in PET Scanners. Quaterly Journal of Nuclear Medicine and Molecular Imaging. 2008;52:151-58.
  11. Lewis JS, Laforest R, Dehdashti F, Grigsby PW, Welch MJ, Siegel BA. An Imaging Comparison of 64Cu-ATSM and 60Cu-ATSM in Cancer of the Uterine Cervix. Journal of Nuclear Medicine. 2008;49:1177-82.
  12. Lewis JS, Welch MJ, Tang L. Workshop on the Production and Application of "Non-Standard" PET Nuclides: A Meeting Report. Quaterly Journal of Nuclear Medicine and Molecular Imaging. 2008;52:101-06.
  13. Li L, Bading J, Yazaki PJ, Ahuja AH, Crow D, Colcher D, et al. A Versatile Bifunctional Chelate for Radiolabeling Humanized Anti-CEA Antibody with In-111 and Cu-64 at Either Thiol or Amino Groups: PET Imaging Of CEA-Positive Tumors with Whole Antibodies. Bioconjugate Chemistry. 2008;19:89-96.
  14. Li WP, Meyer LA, Capretto DA, Sherman CD, Anderson CJ. Receptor-Binding, Biodistribution, and Metabolism Studies of 64Cu-DOTA-Cetuximab, a PET-Imaging Agent for Epidermal Growth-Factor Receptor-Positive Tumors. Cancer Biotherapy & Radiopharmaceuticals. 2008;23:158-71.
  15. Nahrendorf M, Zhang H, Hembrador S, Panizzi P, Sosnovik DE, Aikawa E, et al. Nanoparticle PET-CT Imaging of Macrophages in Inflammatory Atherosclerosis. Circulation. 2008;117:379-87.
  16. Rossin R, Muro S, Welch MJ, Muzykantov VR, Schuster DP. In Vivo Imaging of 64Cu-Labeled Polymer Nanoparticles Targeted to the Lung Endothelium. Journal of Nuclear Medicine. 2008;49:103-11. 17.
  17. Safaei R, Otani S, Larson BJ, Rasmussen ML, Howell SB. Transport of Cisplatin by the Copper Efflux Transporter ATP7B. Molecular Pharmacology. 2008;73:461-68.
  18. Tai Y-C, Wu H, Pal D, O'Sullivan JA. Virtual-Pinhole PET. Journal of Nuclear Medicine. 2008;49:471-79.
  19. Tang L. Radionuclide Production and Yields at Washington University School of Medicine. Quaterly Journal of Nuclear Medicine and Molecular Imaging. 2008;52:121-33.
  20. Vãvere AL, Lewis JS. Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines. Nuclear Medicine and Biology. 2008;35:273-79.
  21. Zhang K, Aruva MR, Shanthly N, Cardi CA, Rattan S, Patel C, et al. PET Imaging of VPAC1 Expression in Experimental and Spontaneous Prostate Cancer. Journal of Nuclear Medicine. 2008;49:112-21.
  22. Zhou D, Sharp TL, Fettig NM, Lee H, Lewis JS, Katzenellenbogen JA, et al. Evaluation of a Bromine-76-labeled Progestin 16α,17α-dioxolane for Breast Tumor Imaging and Radiotherapy: in vivo Biodistribution and Metabolic Stability Studies. Nuclear Mediciine and Biology. 2008;(in Press).
  23. Zhou D, Zhou H, Jenks C, Lewis JS, Katzenellenbogen JA, Welch MJ. Bromination from Microscopic to Radiochemical: 76Br Radiolabeling of Aromatic Compounds via Electrophilic Substitution. Journal of Organic Chemistry. 2008;(under Review).
Return to top

 2007
  1. Backer MV, Levashova Z, Patel V, Jehning BT, Claffey K, Blankenberg FG, et al. Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nature Medicine. 2007;13:504-09.
  2. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proceedings of the National Academy of Sciences. 2007;104:15549-54.
  3. Biddlecombe GB, Rogers BE, de Visser M, Parry JJ, de Jong M, Erion JL, et al. Molecular Imaging of Gastrin-Releasing Peptide Receptor-Positive Tumors in Mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-Bombesin(1-14). Bioconjugate Chemistry. 2007;18:724-30.
  4. Cai W, Chen K, He L, Cao Q, Koong A, Chen X. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. European Journal of Nuclear Medicine and Molecular Imaging. 2007;34:850-58.
  5. Cheng Z, Xiong Z, Subbarayan M, Chen X, Gambhir SS. 64Cu-Labeled Alpha-Melanocyte-Stimulating Hormone Analog for MicroPET Imaging of Melanocortin 1 Receptor Expression. Bioconjugate Chem. 2007;18:765-72.
  6. Chou DK, Zhao Y, Gao S, Chou I-N, Toselli P, Stone P, et al. Perturbation of Copper (Cu) Homeostasis and Expression of Cu-Binding Proteins in Cadmium-Resistant Lung Fibroblasts. Toxicological Sciences. 2007;99:267-76.
  7. Eiblmaier M, Andrews R, Laforest R, Rogers BE, Anderson CJ. Nuclear Uptake and Dosimetry of 64Cu-Labeled Chelator Somatostatin Conjugates in an SSTr2-Transfected Human Tumor Cell Line. Journal of Nuclear Medicine. 2007;48:1390-96.
  8. Green MA, Mathias CJ, Willis LR, Handab RK, Lacy JL, Millerd MA, et al. Assessment of Cu-ETS as a PET radiopharmaceutical for evaluation of regional renal perfusion. Nuclear Medicine & Biology. 2007;34:247-55.
  9. Grigsby P, Malyapa R, Higashikubo R, Schwarz J, Welch M, Huettner P, et al. Comparison of Molecular Markers of Hypoxia and Imaging with 60Cu-ATSM in Cancer of the Uterine Cervix. Molecular Imaging and Biology. 2007;9:278-83.
  10. Heroux KJ, Woodin KS, Tranchemontagne DJ, Widger PCB, Southwick E, Wong EH, et al. The long and short of it: The influence of N-carboxyethyl versus N-carboxymethyl pendant arms on in vitro and in vivo behavior of copper complexes of cross-bridged tetraamine macrocycles. Dalton Transactions. 2007:2150-62.
  11. Kabalka GW, Tang, G., Mereddy, A.R. No-carrier-added radiohalogenations utilizing organoborates. Journal of Labelled Compounds and Radiopharmaceuticals. 2007;50:446-47.
  12. Mach RH, Wheeler KT. Imaging the proliferative status of tumors with PET. Journal of Labelled Compounds and Radiopharmaceuticals. 2007;50:366-69.
  13. Parent E, Dence CS, Jenks C, Sharp TL, Welch MJ, Katzenellenbogen JA. Synthesis and biological evaluation of [18F]bicalutamide, 4-[76Br]bromobicalutamide, and 4-[76Br]bromo-thiobicalutamide as non-steriodal androgens for prostate cancer imaging. Journal of Medicinal Chemistry. 2007;50:1028-40.
  14. Parry J, Andrews R, Rogers B. MicroPET Imaging of Breast Cancer Using Radiolabeled Bombesin Analogs Targeting the Gastrin-releasing Peptide Receptor. Breast Cancer Research and Treatment. 2007;101:175-83.
  15. Parry J, Eiblmaier M, Andrews R, Meyer L, Higashikubo R, Anderson C, et al. Characterization of somatostatin receptor subtype 2 expression in stably transfected A-427 human cancer cells. Molecular Imaging. 2007;6:56-67.
  16. Parry JJ, Kelly TS, Andrews R, Rogers BE. In Vitro and in Vivo Evaluation of 64Cu-Labeled DOTA-Linker-Bombesin(7-14) Analogues Containing Different Amino Acid Linker Moieties. Bioconjugate Chem. 2007;18:1110-17.
  17. Pressly ED, Rossin R, Hagooly A, Fukukawa Ki, Messmore BW, Welch MJ, et al. Structural Effects on the Biodistribution and Positron Emission Tomography (PET) Imaging of Well-Defined 64Cu-Labeled Nanoparticles Comprised of Amphiphilic Block Graft Copolymers. Biomacromolecules. 2007;8:3126-34.
  18. Rossin R, Berndorff D, Friebe M, Dinkelborg LM, Welch MJ. Small-Animal PET of Tumor Angiogenesis Using a 76Br-Labeled Human Recombinant Antibody Fragment to the ED-B Domain of Fibronectin. Journal of Nuclear Medicine. 2007;48:1172-79.
  19. Samimi G, Kishimoto S, Manorek G, Breaux J, Howell S. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin. Cancer Chemotherapy and Pharmacology. 2007;59:301-12.
  20. Sinani D, Adle DJ, Kim H, Lee J. Distinct Mechanisms for Ctr1-mediated Copper and Cisplatin Transport. Journal of Biological Chemistry. 2007;282:26775-85.
  21. Sprague JE, Kitaura H, Zou W, Ye Y, Achilefu S, Weilbaecher KN, et al. Noninvasive imaging of osteoclasts in parathyroid hormone-induced osteolysis using a 64Cu-labeled RGD peptide. Journal of Nuclear Medicine. 2007;48:311-18.
  22. Sprague JE, Peng Y, Fiamengo AL, Woodin KS, Southwick EA, Weisman GR, et al. Synthesis, Characterization and In Vivo Studies of Cu(II)-64-Labeled Cross-Bridged Tetraazamacrocycle-amide Complexes as Models of Peptide Conjugate Imaging Agents. Journal Medicinal Chemistry. 2007;50:2527-35.
  23. Sun G, Xu J, Hagooly A, Rossin R, Li Z, Moore DA, et al. Strategies for Optimized Radiolabeling of Nanoparticles for in vivo PET Imaging. Advanced Materials. 2007;19:3157-62.
  24. Tian X, Chakrabarti A, Amirkhanov N, Aruva MR, Zhang K, Cardi CA, et al. Receptor-mediated internalization of chelatorPNApeptide hybridization probes for radioimaging or magnetic resonance imaging of oncogene mRNAs in tumours. Biochemical Society Transactions. 2007;035:72-76.
  25. Vãvere AL, Lewis JS. CuATSM: A radiopharmaceutical for the PET imaging of hypoxia. Dalton Transactions. 2007:4893-902.
  26. Voss SD, Smith SV, DiBartolo N, McIntosh LJ, Cyr EM, Bonab AA, et al. Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr immunoconjugates. Proceedings of the National Academy of Sciences. 2007;104:17489-93.
  27. Wadas TJ, Anderson, C.J. . Radiolabeling of TETA- and CB-TE2A-conjugated peptides with copper-64. Nature Protocols. 2007;1:3062-68
  28. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Copper chelation chemistry and its role in copper radiopharmaceuticals. Current Pharmaceutical Design. 2007;13:3-16.
  29. Wang J, Yang CT, Kim YS, Sreerama SG, Cao Q, Li ZB, et al. 64Cu-Labeled Triphenylphosphonium and Triphenylarsonium Cations as Highly Tumor-Selective Imaging Agents. Journal of Medicinal Chemistry. 2007;50:5057-69.
  30. Wei L, Butcher C, Miao Y, Gallazzi F, Quinn TP, Welch MJ, et al. Synthesis and Biological Evaluation of Cu-64 labeled Rhenium-Cyclized α-MSH Peptide Analog Using a Cross-Bridged Cyclam Chelator. Journal of Nuclear Medicine. 2007;48:64-72.
  31. Wei L, Miao Y, Gallazzi F, Quinn TP, Welch MJ, V�ere AL, et al. Gallium-68-labeled DOTA-rhenium-cyclized α-melanocyte-stimulating hormone analog for imaging of malignant melanoma. Nuclear Medicine and Biology. 2007;34:945-53.
  32. Welch MJ, Laforest R, Lewis JS. Production of Non-Standard PET Radionuclides and the Application of Radiopharmaceuticals Labeled with these Nuclides. PET Chemistry: The Driving Force in Molecular Imaging Series. 2007;159-82.
  33. Xu J, Sun G, Rossin R, Hagooly A, Li Z, Fukukawa K, et al. Labeling of Polymer Nanostructures for Medical Imaging: Importance of Cross-Linking Extent, Spacer Length, and Charge Density. Macromolecules. 2007;40:2971-73.
  34. Yuan JC, You YZ, Lu X, Muzik O, Oupicky D, Peng FY. Synthesis of poly[APMA]-DOTA-Cu-64 conjugates for interventional radionuclide therapy of prostate cancer: Assessment of intratumoral retention by micro-positron emission tomography. Molecular Imaging. 2007;6:10-17.
  35. Zhang K, Aruva MR, Shanthly N, Cardi CA, Patel CA, Rattan S, et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating peptide (PACAP) receptor specific peptide analogues for PET imaging of breast cancer: In vitro/in vivo evaluation. Regulatory Peptides. 2007;144:91-100.
  36. Zhang Y, Kundu B, Fairchild KD, Locke L, Berr SS, Linden J, et al. Synthesis of novel neutrophil-specific imaging agents for Positron Emission Tomography (PET) imaging. Bioorganic and Medicinal Chemistry Letters. 2007;17:6876-78.
  37. Zimnicka AM, Maryon EB, Kaplan JH. Human Copper Transporter hCTR1 Mediates Basolateral Uptake of Copper into Enterocytes: IMPLICATIONS FOR COPPER HOMEOSTASIS. Journal of Biological Chemistry. 2007;282:26471-80.
Return to top

 2006
  1. Bigott HM, Laforest R, Liu X, Ruangma A, Wuest F, Welch MJ. Advances in the production, processing and microPET image quality of technetium-94m. Nuclear Medicine and Biology. 2006;33:923-33.
  2. Cai W, Wu Y, Chen K, Cao Q, Tice DA, Chen X. In vitro and In vivo Characterization of 64Cu-Labeled AbegrinTM, a Humanized Monoclonal Antibody against Integrin αvβ3. Cancer Res. 2006;66:9673-81.
  3. Caruano-Yzermans AL, Bartnikas TB, Gitlin JD. Mechanisms of the copper-dependent turnover of the copper chaperone for superoxide dismutase. Journal of Biological Chemistry. 2006;281:13581-87.
  4. Clifford T, Boswell CA, Biddlecombe GB, Lewis JS, Brechbiel MW. Validation of a Novel CHX-A" Derivative Suitable for Peptide Conjugation: Small Animal PET/CT Imaging using Yttrium-86-CHX-A"-Octreotide. Journal of Medicinal Chemistry. 2006;49:4297-304.
  5. Holzer AK, Manorek GH, Howell SB. Contribution of the Major Copper Influx Transporter CTR1 to the Cellular Accumulation of Cisplatin, Carboplatin, and Oxaliplatin. Molecular Pharmacology. 2006;70:1390-94.
  6. Kabalka GW, Mereddy AR, Green JF. The No-Carrier-Added Synthesis of Bromine-76 Labeled Alkenyl and Alkynyl Bromides Using Organotrifluoroborates. Journal of Labelled Compounds and Radiopharmaceuticals. 2006;49:11-15.
  7. Lee H, Finck BN, Jones LA, Welch MJ, Mach RH. Synthesis and evaluation of a bromine-76-labeled PPARgamma antagonist 2-bromo-5-nitro-N-phenylbenzamide. Nuclear Medicine and Biology. 2006;33:847-54.
  8. Myerson RJ, Singh AK, Bigott HM, Cha B, Engelbach JA, Kim J, et al. Monitoring the effect of mild hyperthermia on tumour hypoxia by Cu-ATSM PET scanning. International Journal of Hyperthermia. 2006;22:93-115.
  9. Ohgami RS, Campagna DR, McDonald A, Fleming MD. The Steap proteins are metalloreductases. Blood. 2006;108:1388-94.
  10. Parent EE, Jenks C, Sharp TL, Welch MJ, Katzenellenbogen JA. Synthesis and biological evaluation of a non-steriodal bromine-76-labeled androgen receptor ligand 3-[76Br]bromo-hydroxyflutamide. Nuclear Medicine and Biology. 2006;33:705-13.
  11. Parry JJ, Andrews R, Rogers BE. MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor. Breast Cancer Res Treat. 2006;101:175-83.
  12. Peng F, Lu X, Janisse J, Muzik O, Shields AF. PET of Human Prostate Cancer Xenografts in Mice with Increased Uptake of 64CuCl2. Journal of Nuclear Medicine. 2006;47:1649-52.
  13. Rowland DJ, Tu Z, Xu J, Ponde D, Mach RH, Welch MJ. Synthesis and in vivo evaluation of 2 high-affinity 76Br-labeled α2-receptor ligands. Journal of Nuclear Medicine. 2006;47:1071-48.
  14. Ruangma A, Bai B, Lewis JS, Sun X, Welch MJ, Leahy R, et al. Imaging with 3-D Maximum a posteriori (MAP) with Radiopharmaceuticals Labeled with Three Copper Radionuclides. Nuclear Medicine Biology. 2006;33:217-26.
  15. Sprague JE, Li WP, Liang K, Achilefu S, Anderson CJ. In vitro and in vivo investigation of matrix metalloproteinase expression in metastatic tumor models. Nuclear Medicine and Biology. 2006;33:227-37.
  16. Wadas T, Anderson C. Radiolabeling of TETA- and CB-TE2A-conjugated peptides with copper-64. Nat Protoc. 2006;1:3062-68.
  17. Wei L, Easmon J, Nagi RK, Muegge BD, Meyer LA, Lewis JS. 64Cu-azabicyclo[3.2.2]nonane thiosemicarbazone complexes: Radiopharmaceuticals for PET of topoisomerase II expression in tumors. Journal of Nuclear Medicine. 2006;47:2034-41.
  18. Yang YS, Zhang X, Xiong Z, Chen X. Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nuclear Medicine and Biology. 2006;33:371-80.
  19. Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). Journal of Nuclear Medicine. 2006;47:989-98.
  20. Zhou D, Carlson KE, Katzenellenbogen JA, Welch MJ. Bromine- and Iodine- Substituted 16α,17α-dioxolane Progestins for Breast Tumor Imaging and Radiotherapy: Synthesis and Receptor Binding Affinity. Journal of Medicinal Chemistry. 2006;49:4737-44.
Return to top

 2005
  1. Bigott HM, Parent E, Luyt LG, Katzenellenbogen JA, Welch MJ. Design and synthesis of functionalized cyclopentadienyl tricarbonymetal complexes for technetium-94m PET imaging of estrogen receptors. Bioconjugate Chemistry. 2005;16:255-264.
  2. Bigott H, Prior JL, Piwnica-Worms DR, Welch MJ. Imaging Multidrug Resistance P-glycoprotein Transport Function Using microPET with Technetium-94m-sestamibi. Molecular Imaging. 2005;4:30-39.
  3. Boswell CA, McQuade P, Weisman GR, Wong EH, Anderson CJ. Optimization of labeling and metabolite analysis of copper-64-labeled azamacrocyclic chelators by radio-LC-MS. Nuclear Medicine and Biology. 2005;32:29-38.
  4. Bryan JN, Jia F, Mohsin H, et al. Comparative uptakes and biodistributions of internalizing versus non-internalizing copper-64 radioimmunoconjugates in cell and animal models of colon cancer. Nucl Med Biol. 2005;32:851-858.
  5. Burgman P, O'Donoghue JA, Lewis JS, Welch MJ, Humm JL, Ling CC. Cell line dependent differences in uptake and retention of the hypoxia selective nuclear imaging agent Cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM). Nuclear Medicine and Biology. 2005;32:623-630.
  6. Chakrabarti A, Aruva MR, Sajankila SP, Thakur ML, Wickstrom E. Synthesis of novel PNA-peptide chimera for non-invasive imaging of cancer. Journal of Nucleosides, Nucleotides and Nucleic Acids. 2005;24:409-414.
  7. Chen X, Sievers E, Hou Y, et al. Integrin alpha(v)beta(3) targeted imaging of lung cancer. Neoplasia. 2005;7:271-279.
  8. Eisses JF, Chi Y, Kaplan JH. Stable plasma membrane levels of hCTR1 mediate cellular copper uptake. Journal of Biological Chemistry. 2005;286:9635-9639.
  9. Laforest R, Dehdashti F, Lewis JS, Schwarz SW. Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET. European Journal of Nuclear Medicine & Molecular Imaging. 2005;32:764-770.
  10. McQuade P, Martin KE, Castle TC, et al. Investigation into 64Cu-labeled Bis(selenosemicarbazone) and Bis(thiosemicarbazone) complexes as hypoxia imaging agents. Nuclear Medicine and Biology. 2005;32:147-156.
  11. McQuade P, Rowland DJ, Lewis JS, Welch MJ. Positron-emitting isotopes produced on biomedical cyclotrons. Current Medicinal Chemistry. 2005;12:807-818.
  12. McQuade P, Miao Y, Yoo J, Quinn TP, Welch MJ, Lewis JS. Imaging of melanoma using 64Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analog of α-MSH. Journal of Medicinal Chemistry. 2005;48:2985-2992.
  13. Miller WH, Hartmann-Siantar C, Fisher D, et al. Evaluation of Beta Absorbed Fractions in a Mouse Model for 90Y, 188Re, 166Ho, 149Pm, 177Lu and 64Cu Radioisotopes. Cancer Biother Radiopharm.2005;20:436-449.
  14. O'Donoghue JA, Zanzonico P, Pugachev A, et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: comparitive study featuring microPET imaging, PO2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. International Journal of Radiation Oncology - Biology - Physics. 2005;61:1493-1502.
  15. Obata A, Kasamatsu S, Lewis JS, et al. Basic characterization of 64Cu-ATSM as a radiotherapy agent. Nuclear Medicine & Biology. 2005;32:21-28.
  16. Olafsen T, Kenanova V, Sundaresan G, et al. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. Cancer Research. 2005;65:5907-5916.
  17. Rossin R, Pan D, Qi K, et al. 64Cu-Labeled folate-Conjugated Shell Cross-Linked Nanoparticles for Tumor Imaging and Radiotherapy: Synthesis, Radiolabeling, and Biologic Evaluation. Journal of Nuclear Medicine. 2005;46:1210-1218.
  18. Sun X, Fang H, Rossin R, Welch MJ, Taylor J-S. MicroPET Imaging of MCF-7 Tumors in Mice via unr mRNA-Targeted Peptide Nucleic Acids. Bioconjugate Chemistry. 2005;16:294-305.
  19. Sun X, Turner JL, Becker ML, et al. An assessment of the effects of shell crosslinked nanoparticle size, core composition, and surface PEGylation on in vivo biodistribution. Biomacromolecules. 2005;6:2541-2554.
  20. Yoo J, Reichert DE, Kim J, Anderson CJ, Welch MJ. A potential Dubin-Johnson syndrome imaging agent: Synthesis, biodistribution and microPET imaging. Molecular Imaging. 2005;4:18-29.
  21. Yoo J, Tang L, Perkins TA, et al. Preparation of High Specific Activity 86Y Using a Small Biomedical Cyclotron. Nucl Med Biol. 2005;32:891-897.
  22. Ruangma A, Bai B, Lewis JS, et al. Imaging with 3-D Maximum a posteriori (MAP) with Radiopharmaceuticals Labeled with Three Copper Radionuclides. Nuclear Medicine Biology. in press.
Return to top

 2004
  1. Boswell CA, Sun X, Niu W, et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. Journal of Medicinal Chemistry 47: 1465-1474, 2004
  2. Chen X, Park R, Tohme M, et al. MicroPET and autoradiographic imaging of breast cancer av-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjugate Chemistry 15: 41-49, 2004
  3. Niu G, Gaut A, Boles Ponto LL, et al. Multimodality noninvasive imaging of gene transfer using the human sodium iodide symporter. Journal of Nuclear Medicine 45(3): 445-449, 2004
Return to top

 2003
  1. Aft RL, Lewis JS, Zhang F, et al. Enhancing targeted radiotherapy by 64Cu-ATSM using 2-deoxy-D-glucose. Cancer Research 63: 5496-5504, 2003
  2. Beattie BJ, Finn R, Rowland D, et al. Quantitative imaging of bromine-76 and yttrium-86 with PET: a method for the removal of spurious activity introduced by cascade gamma rays. Medical Physics 30(9): 2410-2423, 2003
  3. Hamza I, Prohaska J, Gitlin JD. Essential role for Atox1 in the copper-mediated intracellular trafficking of the Menkes ATPase. Proceedings of the National Academy of Sciences 100(3): 1215-1220, 2003
  4. Lewis MR, Wang M, Axworthy DB, et al. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy. Journal of Nuclear Medicine 44(8): 1284-1292, 2003
  5. Luyt LG, Bigott H, Welch MJ, et al. 7 and 17-Substituted estrogens containing tridentate rhenium/technetium complexes: synthesis of estrogen receptor imaging agents and evaluation using microPET with technetium-94m. Bioorganic Medicinal Chemistry 11(23): 4977-4989, 2003
  6. Mathias CJ, Lewis MR, Reichert DE, et al. Preparation of 68Ga-labeled
    Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals. Nuclear Medicine and Biology 30: 725-731, 2003
  7. Obata A, Yoshimoto M, Kasamatsu S, et al. Intra-tumoral distribution of 64Cu-ATSM: a comparison study with FDG. Nuclear Medicine and Biology 30: 529-534, 2003
  8. Petris MJ, Smith K, Lee J, et al. Copper-stimulated endocytosis and degradation of the human copper transporter, hCtr1. Journal of Biological Chemistry 278(11): 9639-9646, 2003
  9. Rogers BE, Bigott HM, McCarthy DW, et al. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. Bioconjugate Chemistry 14(4): 756-763, 2003
  10. Scappaticci FA, Contreras A, Boswell CA, et al. Polyclonal antibodies to xenogeneic endothelial cells induce apoptosis and block support of tumor growth in mice. Vaccine 21: 2667-2677, 2003
  11. Sun X, Wuest M, Kovacs Z, et al. In vivo behavior of copper-64-labeled methanephosphonate tetraazamacrocyclic ligands. Journal of Biological Inorganic Chemistry 8: 217-225, 2003
  12. Wang M, Caruano AL, Lewis MR, et al. Subcellular localization of radiolabelled somatostatin analogues: implications for targeted radiotherapy of cancer. Cancer Research 63: 6864-6869, 2003
  13. Zerounian NR, Redekosky C, Malpe R, et al. Regulation of copper absorption by copper availability in the Caco-2 cell intestinal model. American Journal of Physiology: Gastrointestinal and Liver Physiology 284: G739-G747, 2003
Return to top

 2002
  1. Adonai N, Nguyen KN, Walsh J, et al. Ex vivo cell labeling with 64Cu-pyruvaldehyde-bis(N4-methylthisemicarbazone) for imaging cell trafficking in mice with positron emission tomography. Proceedings of the National Academy of Sciences, 99(5): 3030-3035, 2002
  2. Bigott H, Welch MJ. Technetium-94m-sestamibi: preparation and quality control for human use., in Nicolini M, Mazzi U, (eds): Technetium, Rhenium, and Other Metals in Chemistry and Nuclear Medicine 2002, pp 559-561
  3. Dearling JLJ, Lewis JS, Mullen GED, et al. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. Journal of Biological Inorganic Chemistry 7: 249-259, 2002
  4. Donley SA, Ilagan BJ, Rim H, et al. Copper transport to mammary gland and milk during lactation in rats. American Journal of Physiology: Endocrinology and Metabolism 283: E667-E675, 2002
  5. Eisse JF, Kaplan JH. Molecular characterization of hCtr1, the human copper uptake protein. Journal of Biological Chemistry 227(32): 29162-29171, 2002
  6. Engelhardt EL, Schneider RF, Seeholzer SH, et al. The synthesis and radiolabeling of 2-nitroimidazole derivatives of cyclam and their preclinical evaluation as positive markers of tumor hypoxia. Journal of Nuclear Medicine 43(6): 837-850, 2002
  7. Fan B, Rosen BP. Biochemical characterization of CopA, the Escherichia coli Cu(I)-translocating P-type ATPase. Journal of Biological Chemistry, 277(49): 46987-46992, 2002
  8. Hellman NE, Kono S, Miyajima H, et al. Biochemical analysis of a missense mutation in aceruloplasminemia. Journal of Biological Chemistry, 277: 1375-1380S, 2002
  9. Hellman NE, Gitlin JD. Ceruloplasmin metabolism and function. Annual Review of Nutrition, 22: 439-458, 2002
  10. Hellman NE, Kono S, Mancini GM, et al. Mechanisms of copper incorporation into human ceruloplasmin. Journal of Biological Chemistry, 277(48): 46632-46638, 2002
  11. Ishida S, Lee J, Thiele DJ, et al. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proceedings of the National Academy of Sciences 99(22): 14298-14302, 2002
  12. Katano K, Kondo A, Safaei R, et al. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Research 62: 6559-6565, 2002
  13. Kiani S, Staples RJ, Packard AB. A lariat-functionalized copper(II) diimine-dioxime complex. Acta Crystallographica 58: m593-505, 2002
  14. Laforest R, Rowland DJ, Welch MJ. MicroPET imaging of non-conventional isotopes. IEEE Transactions on Nuclear Science, 49(5): 2119-2126, 2002
  15. Lee J, Pena MMO, Nose Y, et al. Biochemical characterization of human copper transporter Ctr1. Journal of Biological Chemistry, 277: 4380-4387, 2002
  16. Lee J, Petris MJ, Thiele DJ. Characterization of mouse embryonic cells deficient in the Ctr1 high affinity copper transporter. Journal of Biological Chemistry, 277(43): 40253-40259, 2002
  17. Lewis JS, Connett JM, Garbow JR, et al. Copper-64-pyruvaldehyde-bis(N4-methylsemicarbazone) for the prevention of tumor growth at wound sites following laparoscopic surgery: monitoring therapy responses with microPET and magnetic resonance imaging. Cancer Research, 62: 445-449, 2002
  18. Lewis JS, Welch MJ. Copper chemistry related to radiopharmaceutical production. In Nicolini M, Mazzi U, (eds): Technetium, Rhenium, and Other Metals in Chemistry and Nuclear Medicine, 2002, 23-33
  19. Lewis MR, Reichert DE, Laforest R, et al. Production and purification of gallium-66 for preparation of tumor-targeting radiopharmaceuticals. Nuclear Medicine and Biology, 29(6): 701-706, 2002
  20. Li WP, Lewis JS, Kim J, et al. DOTA-D-Tyr1-octreotate: a somatostatin analog for labeling with metal and halogen radionuclides for cancer imaging and therapy. Bioconjugate Chemistry, 13(4): 721-728, 2002
  21. Lin X, Okuda T, Holzer A, et al. The copper transporter Ctr1 regulates cisplatin uptake in Saccharomyces cerevisiae. Molecular Pharmacology 62(5): 1154-1159, 2002
  22. Ma D, Lu F, Overstreet T, et al. Novel chelating agents for potential clinical applications of copper. Nuclear Medicine and Biology, 29(1): 91-105, 2002
  23. Packard AB, Kronauge JF, Barbarics E, et al. Synthesis and biodistribution of a lipophilic 64Cu-labeled monocationic copper(II) complex. Nuclear Medicine and Biology 29(3): 289-294, 2002
  24. Puig S, Lee J, Lau M, et al. Biochemical and genetic analysis of yeast and human high affinity copper transporters suggest a conserved mechanism for copper uptake. Journal of Biological Chemistry, 277(29): 26021-26030, 2002
  25. Riggio M, Lee J, Scudiero R, et al. High affinity copper transport protein in the lizard Podarcis sicula: molecular cloning, functional characterization, and expression in somatic tissues, follicular oocytes, and eggs. Biochimica et Biophysica Acta, 1576: 127-135, 2002
  26. Subramanian JR, Lyons WE, Liu J, et al. Mutant SOD1 causes motor neuron disease independent of CCS-mediated copper loading. Nature Neuroscience, 5: 301-307, 2002
  27. Sun X, Wuest M, Weisman GR, et al. Radiolabeling and in vivo behavior or copper-64-labeled cross-bridged ligands. Journal of Medicinal Chemistry, 45: 469-477, 2002
  28. Vavere AL, Lewis JS, Welch MJ. Imaging of anti-angiogenic treatments: Ti-45-transferrin microPET as a surrogate marker for tumor response., in Nicolini M, Mazzi U, (eds): Technetium, Rhenium, and Other Metals in Chemistry and Nuclear Medicine 2002, pp 101-105
  29. Wipke BT, Wang Z, Kim J, et al. Dynamic visualization of a joint-specific autoimmune response through positron emission tomography. Nature Immunology, 3(4): 366-372, 2002
  30. Zerounian NR, Linder MC. Effects of copper and ceruloplasmin on iron transport in Caco-2 cell intestinal model. The Journal of Nutritional Biochemistry 13: 138-148, 2002
Return to top

 2001
  1. Bartnikas TB, Gitlin JD. How to make a metalloprotein. Nature Structural Biology, 8: 733-734, 2001
  2. Edwards WB, Anderson CJ, Fields GB, et al. Evaluation of radiolabeled type IV collagen fragments as potential tumor imaging agents. Bioconjugate Chemistry, 12(6): 1057-1065, 2001
  3. Fan B, Grass G, Rensing C, et al. Escherichia coli CopA N-terminal Cys(X)2Cys motifs are not required for copper resistance or transport. Biochemical and Biophysical Research Communications 286: 414-418, 2001
  4. Hamza I, Faisst A, Prohaska J, et al. The metallochaperone Atox1 plays a critical role in perinatal copper homeostasis. Proceedings of the National Academy of Sciences, 98(12): 6848-6852, 2001
  5. Hamza I, Gitlin JD. Copper metabolism and the liver. In Arias IM, Boyer JB, Chisari F, Fausto N, Schachter D, Shafritz D, (eds): The Liver: Biology and Pathobiology 3rd ed., Lippincott, Wilkins and Wilkins, 2001
  6. Lewis JS, Sharp TL, Laforest R, et al. Tumor uptake of copper-64-diacetyl-bis(N4-methylsemicarbazone): effect of changes in tissue oxygenation. Journal of Nuclear Medicine, 42: 655-661, 2001
  7. Lewis JS, Laforest R, Buettner TL, et al. Copper-64-diacetyl-bis(N4-methylsemicarbazone): an agent for radiotherapy. Proceedings of the National Academy of Sciences, 98(3): 1206-1211, 2001
  8. Lewis JS, Welch MJ. PET imaging of hypoxia. Quarterly Journal of Nuclear Medicine, 45(2):183-188, 2001.
  9. Lewis MR, Boswell CA, Laforest R, et al. Conjugation of monoclonal antibodies with TETA using activated esters: biological comparison of 64Cu-TETA-1A3 with 64Cu-BAT-2IT-1A3. Cancer Biotherapy and Radiopharmaceuticals, 16: 483-494, 2001
  10. McLoughlin DM, Standen CL, Lau KF, et al. The neuronal adaptor protein X11a interacts with the copper chaperone for SOD1 and regulates SOD1 activity. The Journal of Biological Chemistry, 276: 9303-9307, 2001
  11. Meyer LA, Durley AP, Prohaska JR et al. Copper transport and metabolism are normal in aceruloplasminemic mice. Journal of Biological Chemistry, 276(39): 36857-36861, 2001
Return to top

 2000
  1. Cutler CS, Wuest M, Anderson CJ, et al. Labeling and in vivo evaluation of novel copper(II) dioxotetraazamacrocyclic complexes. Nuclear Medicine and Biology 27: 375-380, 2000
  2. Harris ZL, Durley AP, Man TK, et al. Targeted gene disruption reveals an essential role for ceruloplasmin in cellular iron efflux. Proceedings of the National Academy of Sciences, 96(19): 10812-10817, 2000
  3. Lewis JS, Laforest R, Lewis MR, et al. Comparative dosimetry of copper-64 and yttrium-90 labeled somatostatin analogs in a tumor-bearing rat model. Cancer Biotherapy and Radiopharmaceuticals, 15(6): 593-604, 2000
  4. Rensing C, Fan B, Sharma R, et al. CopA: An Escherichia coli Cu(I)-translocating P-type ATPase. Proceedings of the National Academy of Sciences, 97(2): 652-656, 2000
  5. Sharma V, Beatty A, Wey S-P, et al. Novel gallium(III) complexes transported by MDR1 P-glycoprotein: potential PET imaging agents for probing P-glycoprotein-mediated transport activity in vivo. Chemistry and Biology 7: 335-343, 2000
  6. Welch MJ, McCarthy TJ. Generator-produced radiopharmaceuticals in clinical PET. Journal of Nuclear Medicine, 41(2): 315-317, 2000
  7. Wu AM, Yazaki PJ, Tsai SW, et al. High-resolution microPET imaging of carcinoembryonic antigen (CEA)-positive xenografts using a copper-64 labeled engineered antibody fragment. Proceedings of the National Academy of Sciences, 97(15): 8495-8500, 2000
Return to top  2000
  1. Dearling JLJ, Mullen GED, Lewis JS, et al. Hypoxia-selective copper-64 complexes, in Nicolini M, Mazzi U, (eds): Technetium, Rhenium, and Other Metals in Chemistry and Nuclear Medicine 1999, pp 599-605
Return to top
Abstracts
 2004
  1. Chen, X, Hou, Y, Park, R, et al. Evaluation of 64Cu-labeled [lys3] bombesin as a PET tracer for prostate cancer GRP receptor imaging. To be presented at Acadamey of Molecular Imaging Conference, Orlando, FL, 2004
  2. Li, WP, Sprague, JE, Rutlin, JR, et al. Molecular imaging of matrix metalloproteinases expression in metastatic tumors using a radiolabeled inhibitor and microPET. To be presented at Acadamey of Molecular Imaging Conference, Orlando, FL, 2004
Return to top

 2003
  1. Anderson, CJ, Caruano, AL, Meyer, LA, et al. Subcellular localization of copper-64 and indium-111-labeled somatostatin analogs: implications for targeted radiotherapy of cancer. Proceedings of the Midwest Metals Meeting, P1, 2003
  2. Anderson, CJ, Li, WP, Kozlowski, J, et al. Evaluation of Cu-64-DOTA-CTT, a MMP-9 inhibitor, as a potential PET lung inflammation imaging agent. Journal of Labelled Compounds and Radiopharmaceuticals, 46:S92, 2003
  3. Bigott, H, Luyt, LG, Welch, MJ, et al. Synthesis of rhenium/technetium labeled estrogen receptor imaging agents: evaluation using microPET with technetium-94m. Journal of Labelled Compounds and Radiopharmaceuticals, 46:S8, 2003
  4. Boswell, CA, Sun, X, Weisman, GR, et al. In vivo stability of CU-64-azamacrocyclic complexes: comparison of TETA and DOTA with cross-bridged chelators. Journal of Labelled Compounds and Radiopharmaceuticals, 46:S67, 2003
  5. Bryan, JN, Lewis, MR, Henry, CJ, et al. Copper-64-labeled antibodies for radioimmunotherapy of cancer. Proceedings of the Veterinary Cancer Society, 6, 2003
  6. Hamza, I, Faisst, A, Gruss, P, et al. Cell biology of the metallochaperone ATOX1. Proceedings of the Midwest Metals Meeting, T21, 2003
  7. Holzer A, Samimi G, Katano K, et al. The role of human copper transporter hCTR1 in cisplatin uptake in human ovarian carcinoma cells. Proceedings of the American Association for Cancer Research Meeting, 44:924, 2003
  8. Katano K, Safaei R, Samimi G, et al. Expression of the copper efflux transporter ATP7B in human ovarian carcinoma cells alters cisplatin and carboplatin sensitivity and cellular pharmacology. Proceedings of the American Association for Cancer Research Meeting, 44:923, 2003
  9. Laforest, R, Ruangma, A, Lewis, JS, et al. MicroPET imaging of radiopharmaceuticals labeled with three copper radionuclides. Journal of Labelled Compounds and Radiopharmaceuticals, 46:S68, 2003
  10. Lewis, JS, Easmon, JR, Rutlin, JR, et al. 64Cu-complexes targeted at topoisomerase-II a regulatory enzyme for DNA topology. Journal of Labelled Compounds and Radiopharmaceuticals, 46:S388, 2003
  11. Lewis, JS, Aft, RL, Zhang, F, et al. MicroPET imaging of the effects of tumorcidal 2-deoxyglucose. Journal of Labelled Compounds and Radiopharmaceuticals, 46:S80, 2003
  12. Li WP, Sprague JE, Anderson CJ. A radiolabeled gelatinase inhibitor for PET imaging of matrix metalloproteinase 2 and 9 expression in a murine melanoma mouse model. Proceedings of the American Association for Cancer Research Meeting, 44:779, 2003
  13. McQuade, P, Jones, LA, Vanderheyden, JL, et al. 94mTc and 64Cu labeled annexin-V, positron emitting radiopharmaceuticals to study apoptosis. Journal of Labelled Compounds and Radiopharmaceuticals, 46:S335, 2003
  14. McQuade, P, Lewis, JS, Martin, K, et al. Investigation into improved imaging agents for cardiovascular and neurologic hypoxia. Journal of Labelled Compounds and Radiopharmaceuticals, 46:S336, 2003
  15. McQuade, P, Lewis, JS, Quinn, TP, et al. 64Cu labeling and evaluation of the metallopeptide, DOTA- ReCCMSG(Arg11), a cyclized α-MSH analogue. Journal of Labelled Compounds and Radiopharmaceuticals, 46:S102, 2003
  16. Okuda, T, Lin, X, Wu, F, et al. The copper transporter CTR1 modulates selenite uptake in Saccharomyces cerevisiae. Proceedings of the American Association for Cancer Research Meeting, 44:140, 2003
  17. Olafsen, T, Tan, GJ, Park, JM, et al. Tumor targeting, biodistribution and microPET imaging of engineered anti-HER2/NEU antibody fragments in xenograft-bearing mice. Journal of Nuclear Medicine, 44:363P, 2003
  18. Reichert, DE, Matsui, K, Wang, Z, et al. Approaches to the in vivo PET imaging of T-cells in adoptive immunotheraphy. Journal of Labelled Compounds and Radiopharmaceuticals, 46:S332, 2003
  19. Robinson, MR, Schneider, R, Doss, M, et al. PET Imaging of human tumor xenografts in a mouse model using iodine-124 and copper-64 labeled anti-her2 diabodies. Molecular Imaging and Biology, 5:170, 2003
  20. Rogers, BE, Manna, DD, Andrews, RD, et al. In vitro evaluation of human cancer cell lines stably expressing somatostatin receptor subtype 2. Journal of Labelled Compounds and Radiopharmaceuticals, 46:S398, 2003
  21. Rowland, DJ, Tu, Z, Mach, RH, et al. Investigation of a new sigma 2 receptor ligand for detection of breast cancer. Journal of Labelled Compounds and Radiopharmaceuticals, 46:S6, 2003
  22. Ruangma, A, Laforest, R, Lewis, JS, et al. Initial evaluation of USC-MAP for imaging of radiopharmaceuticals labeled with three copper radionuclides. Molecular Imaging and Biology, 5:125, 2003
  23. Samimi, G, Varki, NM, Wilczynski, S, et al. Expression of the copper transporter ATP7A is associated with poor survival of ovarian cancer patients treated with platinum drugs. Proceedings of the American Association for Cancer Research Meeting, 44:923, 2003
  24. Samimi, G, Katano, K, Holzer, AK, Safaei, R, et al. The copper export transporters ATP7A and ATP7B modulate the cellular pharmacology of cisplatin and carboplatin. Proceedings of the American Association for Cancer Research Meeting, 44:924, 2003
  25. Sprague, JE, Sun, X, Chang, CH, et al. In vivo behavior of copper-64 labeled Y3-octreotate using a cross-bridged cyclam ligand. Journal of Labelled Compounds and Radiopharmaceuticals, 46:S66, 2003
  26. Sun, X, Turner, JL, Becker, ML, et al. J. In vivo evaluation of copper-64-labeled core-shell nanoparticles utilizing microPET with technetium-94m. Journal of Labelled Compounds and Radiopharmaceuticals, 46:S86, 2003
  27. Sun, X, Bakewell, SJ, Garbow, JR, et al. Multi-modality imaging studies on osteolytic bone metastasis. Journal of Labelled Compounds and Radiopharmaceuticals, 46:S79, 2003
  28. Tang, L, Gaehle, GG, Lewis, JS, et al. Automated separation and labeling systems for copper isotopes (60Cu, 61Cu, and 64Cu). Journal of Labelled Compounds and Radiopharmaceuticals, 46:S281, 2003
  29. Tang, L, Rowland, DJ, Sultan, DH, et al. Remote separation procedure for halogen production. Journal of Labelled Compounds and Radiopharmaceuticals, 46:S49, 2003
  30. Thakur, ML, Aruva, MR, Bolewska-Pedyczak, E, et al. Preparation of Cu-64 and Tc-99m-N2S2-vasoactive intestinal peptide (VIP) for imaging and gene expression. Journal of Labelled Compounds and Radiopharmaceuticals, 46:S128, 2003
  31. Vavere, AL and Welch, MJ. MicroPET imaging of titanium-45 labeled titanocene complex to delineate biodistribution of titanium anti-cancer drugs. Journal of Labelled Compounds and Radiopharmaceuticals, 46:S103, 2003
  32. Wang, Z, Wipke, BT, Reichert, D, et al. MicroPET imaging studies of the initiation and progression of a murine model of rheumatoid arthritis. Journal of Labelled Compounds and Radiopharmaceuticals, 46:S91, 2003
  33. Wang, ZJ, Welch, MJ, Rutlin, JR, et al. MicroPET imaging in autoimmune uveitis: asymmetric lymphadenopathy in the secondary lymphoid system. Journal of Nuclear Medicine, 44:313P, 2003
  34. Yoo, J, Reichert, DE, Wolohan, P, et al. Regioselectively N-substituted cyclens: synthesis, biodistribution, log P and modeling.
  35. Journal of Labelled Compounds and Radiopharmaceuticals
    36. , 46:S70, 2003
Return to top

 2002
  1. Anderson CJ, Li WP, Lewis JS, et al. 64Cu-DOTA-CTTHWGFTLC, a radiolabeled gelatinase inhibitor for PET imaging of metastatic breast cancer. Proceedings of the Era of Hope Department of Defense Breast Cancer Research Program Meeting, Orlando, FL, 2002
  2. Green MA, Willis, LR, Mathias CJ, et al. Evaluation of Cu-ETS as a PET radiopharmaceutical for quantification of regional renal perfusion. Molecular Imaging and Biology, 4:S51, 2002
  3. Lewis JS, Ye D, Connett JM, et al. Intratumoral administration of 64Cu-ATSM or 61Cu-ATSM: therapeutic comparison in GW39 tumors. Journal of Nuclear Medicine, 43:279P, 2002
  4. Li WP, Lewis JS, Eiblmaier M, et al. In vitro and in vivo evaluation of a radiolabeled gelatinase inhibitor for microPET® imaging of metastatic breast cancer. Molecular Imaging and Biology, 4(4) S23 2002
  5. Li WP, Lewis JS, Kim JY, et al. A new somatostatin analog for radiolabeled with metals and halogens: copper-64/61 and iodine-125-labeled DOTA-D-Tyr1-octreotate. Journal of Nuclear Medicine, 43:92P, 2002
  6. Li WP, Lewis JS, Lan S, et al. Copper-64-DOAT-CTTHWGFTLC, a selective gelatinase inhibitor for tumor imaging. Journal of Nuclear Medicine, 43:227P, 2002
  7. McCarthy DW, Bigott HM, Rowland DJ, et al. A research resource in radionuclide research. Ninth International Workshop on Targetry and Target Chemistry, E08, 2002
  8. Olafsen T, Cheung C, Yazaki PJ, et al. Engineered anti-CEA antibody fragment allows site-specific conjugation and radiolabeling for tumor targeting applications. Molecular Imaging and Biology, 4:S39, 2002
  9. Olafsen T, Giselle TJ, Park JM, et al. Evaluating two different minibodies, (SCFV-CH3)2, against HER2/NEU for imaging of breast cancer. Proceedings of the Era of Hope Department of Defense Breast Cancer Research Meeting, 2:15, 2002
  10. Rowland DJ, Kim J, Laforest R, et al. Dependence of microPET® resolution on the energy window and normalization for bromine-76. Molecular Imaging and Biology, 4:S40, 2002
  11. Rowland DJ, Laforest R, McCarthy TJ, et al. The present status of a high current inclined target and solid target changer at Washington University. Ninth International Workshop on Targetry and Target Chemistry, C07, 2002
  12. Sun X, Kim J, Bigott H, et al. A potential bone-imaging agent: copper-64-labeled 1,4,7,10-tetraazacyclododecane-1,4,7-tri(methanephosphoric acid). Journal of Nuclear Medicine, 43:136P, 2002
  13. Wang Z, Sharp TL, Bora NS, et al. Approaches toward the in vivo imaging of experimental acute autoimmune uveitis(EAAU). Journal of Labelled Compounds and Radiopharmaceuticals, 44:S372, 2002
  14. Wipke BT, Wang Z, Reichert DE, et al. Dynamic microPET® studies of the initiation and mechanism of an antibody-mediated joint-specific murine model of rheumatoid arthritis. Molecular Imaging and Biology, 4:S37, 2002
  15. Wu AM, Sundaresan G, Li L, et al. Novel radiolabeled antibody fragments for rapid tumor targeting and imaging by PET. Proceedings of the Era of Hope Department of Defense Breast Cancer Research Meeting, 1:7, 2002
  16. Yoo J, Reichert DE, Kim J, et al. A lipophilic DO3A-based cyclen complex of Cu-64: synthesis, biodistribution study and microPET imaging. Journal of Nuclear Medicine, 43:136P, 2002
Return to top

 2001
  1. Boswell CA, Sun X, Wang M, et al. Relationship between reduction potential and in vivo stability of copper-azamacrocyclic complexes. Journal of Labelled Compounds and Radiopharmaceuticals, 44:S770, 2001
  2. Chen X, Edwards WB, Anderson CJ, et al. Solid phase synthesis of TETA conjugated vasoactive intestinal peptide and in vivo behavior of copper-64 radiolabeled vip conjugate. Journal of Labelled Compounds and Radiopharmaceuticals, 44:S688, 2001
  3. Kiani S, Packard A. Radiosynthesis and in vitro study of 64Cu-labeled diiminodioxime complexes as putative PET imaging agents for evaluation of multidrug resistance (MDR). The Quarterly Journal of Nuclear Medicine, 45:S3, 2001
  4. Knight LC, McCarthy DW, Romano JE, et al. Preliminary evaluation of radiolabeled bitistatin as a potential agent for targeting integrins in tumor angiogenesis with PET. Journal of Labelled Compounds and Radiopharmaceuticals, 44:S84, 2001
  5. Laforest R, Rowland DJ, Welch MJ. Characterization of non-conventional isotopes for microPET imaging. High Resolution Imaging in Small Animals: Instrumentation, Applications and Animal Handling, Rockville, Maryland, 2001
  6. Laforest R, Rowland DJ, Welch MJ. Imaging of "non-standard" PET nuclides using the microPET®. Journal of Labelled Compounds and Radiopharmaceuticals, 44:S457, 2001
  7. Lewis JS, Connett JM, Garbow JR, et al. 64Cu-PTSM as an inhibitor of tumor recurrence. Journal of Labelled Compounds and Radiopharmaceuticals, 44:S87, 2001
  8. Lewis JS, Garbow JR, Kim JY, et al. MRI and microPET imaging of tumor progression in hamster abdomens following laparoscopic surgery and radiotherapy. High Resolution Imaging in Small Animals: Instrumentation, Applications and Animal Handling, Rockville, Maryland, 2001
  9. Li WP, Lewis JS, Srinivasan A, Schmidt MA, et al. Copper-64/61 and iodine-125 labeled DOTA-D-TYR-octreotate: a new somatostatin analog for labeling with metals and halogens. Journal of Labelled Compounds and Radiopharmaceuticals, 44:S948, 2001
  10. Luyt LG, Mull ES, Katzenellenbogen JA, et al. Preparation of cyclopentadienyltricarbonyl technetium-94m complexes. Journal of Labelled Compounds and Radiopharmaceuticals, 44:S489, 2001
  11. McCarthy DW, Bigott HM, Rogers BE, et al. A research resource in radionuclide research. Journal of Labelled Compounds and Radiopharmaceuticals, 44:S817, 2001
  12. Rogers BE, McCarthy DW, Sharp TL, et al. Evaluation of a 64Cu-labeled bombesin analogue for diagnosis of gastrin-releasing peptide receptor positive tumors by microPET® imaging. Journal of Labelled Compounds and Radiopharmaceuticals, 44:S81, 2001
  13. Rowland DJ, Laforest R., McCarthy TJ, et al. Conventional and induction furnace distillation procedures for the routine production Br-76, 77 and I-124 on disk and slanted targets. Journal of Labelled Compounds and Radiopharmaceuticals, 44:S1059, 2001
  14. Sharp TL, Engelbach JA, Welch MJ. Procedures for Animal Handling in microPET® Studies. The Quarterly Journal of Nuclear Medicine, 45:S14, 2001
  15. Sun X, Wuest M, Kovacs Z, et al. The in vivo evaluation of copper-64 radiolabeled DO2P, DO3P and DOTP complexes. Journal of Labelled Compounds and Radiopharmaceuticals, 44:S781, 2001
  16. Sun X, Anderson CJ, Wst M, et al. Copper-64 radiolabeling and in vivo behavior of 4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicycle[6.6.2]hexadecane. Journal of Labelled Compounds and Radiopharmaceuticals, 44:S784, 2001
  17. Uetrecht PA, McCarthy TJ, Rowland DJ, et al. Radiotoxicity of bromine and fluorine radiolabeled estrogens in MCF-7 cell culture. Journal of Labelled Compounds and Radiopharmaceuticals, 44:S721, 2001
  18. Wang M, Caruano AL, Lewis MR, et al. Subcellular fractionation of copper-64-TETA-octreotide in AR42J rat pancreatic tumor cells. The Quarterly Journal of Nuclear Medicine, 45:S12, 2001
  19. Wang Z, Garbow JR, Matsui K, et al. In Vivo imaging of Aadoptive immunotherapy: the CMS5/DUC18 tumor ablation model. High Resolution Imaging in Small Animals: Instrumentation, Applications and Animal Handling, Rockville, Maryland, 2001
  20. Wang Z, Sharp TL, Bora NS, et al. Approaches towards the in vivo imaging of experimental acute autoimmune uveitis (EAAU). Journal of Labelled Compounds and Radiopharmaceuticals, 44: S372, 2001
  21. Yoo J, Reichert D, Welch MJ. New N-substituted cyclens: synthesis and comparative biodistribution studies of Cu-64 complexes. Journal of Labelled Compounds and Radiopharmaceuticals, 44:S796, 2001
Return to top

 2000
  1. Adonai N, Nguyen K, Walsh J, et al. Ex Vivo Cu-PTSM labeling of cells as a method to image in vivo cell trafficking with PET. Journal of Nuclear Medicine, 41(5): 256P, 2000.
  2. Laforest R, Lewis JS, Lewis MR, et al. Dosimetry comparisons of 90Y- and 64Cu-labeled somatostatin peptides in tumor bearing animals. Journal of Nuclear Medicine, 41(5): 235P, 2000
  3. Lewis JS, Buettner TL, Connett JM, et al. 64Cu-ATSM as a radiotherapeutic agent: extended survival in GW39 tumor-bearing hamsters. Journal of Nuclear Medicine, 41(5): 115P, 2000
  4. Lewis JS, Connett JA, Buettner Tlet al. 64Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone)(64Cu-PTSM) as a radiotherapy agent to prevent the growth of tumors at wound sites following laparoscopy. European Journal of Nuclear Medicine, 8: 952, 2000
  5. Lewis JS, Sharp TL, Jones LA, et al. Selective 60/64Cu-ATSM uptake in hypoxic tumors correlated with direct tissue oxygen measurement, PET imaging and electronic autoradiography. Journal of Nuclear Medicine, 41(5): 115P, 2000
  6. Lewis MR, Wang M, Jones LA, et al. Radiotherapy and toxicity of 64Cu agents for one- and three-step radioimmunotherapy. Journal of Nuclear Medicine, 41(5): 143P, 2000
  7. Mathias CJ, Lewis MR, Reichert DE, et al. Production of 66Ga for tumor imaging using PET and an athymic mouse model. Journal of Nuclear Medicine, 41(5): 42P, 2000
  8. Sharp TL, Lewis JS, Herrero P, et al. Quantification of Cu-ATSM kinetics by compartmental modeling in normal, ischemic and necrotic myocardium. Journal of Nuclear Medicine, 41(5): 175P, 2000
  9. Welch MJ, Lewis MR, Reichert DE, et al. Production and evaluation of gallium-66 radiopharmaceuticals for PET. European Journal of Nuclear Medicine, 8: 1221, 2000
  10. Wuest M, Partyka DV, Lewis JS, et al. Synthesis and in vitro evaluation of 64Cu-cyclen-N, N', N'', N'''-tetrapropionitrile. Journal of Nuclear Medicine, 41(5): 82P, 2000
Return to top
[ Home ] [ Isotopes ] [ Images ] [ Facilities ] [ Publications ] [ Contact ]